Boston Scientific(US:BSX) Businesswire·2026-03-12 19:04Core Viewpoint - Boston Scientific Corporation (BSX) is facing a securities fraud class action lawsuit due to disappointing financial results and misleading statements regarding its U.S. Electrophysiology (EP) segment growth [1] Financial Performance - On February 4, 2026, Boston Scientific reported its fourth quarter and full year 2025 results, highlighting a shortfall in U.S. Electrophysiology sales and issuing fiscal 2026 guidance that fell below market expectations [1] - The company's stock price dropped by $16.12, or 17.6%, closing at $75.50 per share following the announcement [1] Class Action Details - The class action lawsuit is on behalf of investors who acquired Boston Scientific securities between July 23, 2025, and February 3, 2026 [1] - The lawsuit alleges that the company made materially false and misleading statements and failed to disclose adverse facts about its business and growth prospects [1] Allegations Against the Company - The complaint claims that Boston Scientific's U.S. EP segment growth rate was unsustainable and that new competition was negatively impacting its market share [1] - It is alleged that the company's previous statements of confidence regarding the EP division's growth trajectory were materially misleading [1]